Cancer immunotherapy using NKG2D and DNAM-1 systems

Takashi Morisaki, Hideya Ohnishi, Mitsuo Katano

Research output: Contribution to journalReview article

35 Citations (Scopus)

Abstract

Although tumor antigen-specific immunotherapy, such as dendritic cell vaccine, has recently emerged as a promising clinical approach, one limitation of tumor antigen- and T-cell receptor (TcR)- specific immunotherapy is antigen-specific inhibition by antigen-specific regulatory T-cell and myeloid suppressor cells. Therefore, immunotherapy using a TcR-independent mechanism may be an alternative immunotherapeutic strategy. NKG2D (natural killer, group 2, member D) and DNAX accessory molecule-1 (DNAM-1) are both activated receptors that are strongly expressed on T-cells, γδT-cells, and NK cells. Therefore, the expression of ligands for NKG2D and DNAM-1 on tumor cells plays an important role in tumor opsonization by immune effector cell targeting. Various modulatory methods for up-regulating NKG2D and DNAM-1-ligands have been reported, and included chemotherapeutic agents and hyperthermia. Although there are many obstacles to the utilization of NKG2D and DNAM-1 for cancer therapy, combined treatments using immune cell therapy and chemotherapy that take advantage of NKG2D and DNAM-1 may be an ideal approach.

Original languageEnglish
Pages (from-to)2241-2247
Number of pages7
JournalAnticancer Research
Volume32
Issue number6
Publication statusPublished - Jun 2012

Fingerprint

Immunotherapy
Neoplasm Antigens
Neoplasms
T-Cell Antigen Receptor
Ligands
T-Lymphocytes
Antigens
Regulatory T-Lymphocytes
Myeloid Cells
Cell- and Tissue-Based Therapy
Natural Killer Cells
Dendritic Cells
Fever
Vaccines
CD226 antigen
Drug Therapy
Therapeutics

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Morisaki, T., Ohnishi, H., & Katano, M. (2012). Cancer immunotherapy using NKG2D and DNAM-1 systems. Anticancer Research, 32(6), 2241-2247.

Cancer immunotherapy using NKG2D and DNAM-1 systems. / Morisaki, Takashi; Ohnishi, Hideya; Katano, Mitsuo.

In: Anticancer Research, Vol. 32, No. 6, 06.2012, p. 2241-2247.

Research output: Contribution to journalReview article

Morisaki, T, Ohnishi, H & Katano, M 2012, 'Cancer immunotherapy using NKG2D and DNAM-1 systems', Anticancer Research, vol. 32, no. 6, pp. 2241-2247.
Morisaki, Takashi ; Ohnishi, Hideya ; Katano, Mitsuo. / Cancer immunotherapy using NKG2D and DNAM-1 systems. In: Anticancer Research. 2012 ; Vol. 32, No. 6. pp. 2241-2247.
@article{983a90eb5e2f4ae6ba2eaa92965587b1,
title = "Cancer immunotherapy using NKG2D and DNAM-1 systems",
abstract = "Although tumor antigen-specific immunotherapy, such as dendritic cell vaccine, has recently emerged as a promising clinical approach, one limitation of tumor antigen- and T-cell receptor (TcR)- specific immunotherapy is antigen-specific inhibition by antigen-specific regulatory T-cell and myeloid suppressor cells. Therefore, immunotherapy using a TcR-independent mechanism may be an alternative immunotherapeutic strategy. NKG2D (natural killer, group 2, member D) and DNAX accessory molecule-1 (DNAM-1) are both activated receptors that are strongly expressed on T-cells, γδT-cells, and NK cells. Therefore, the expression of ligands for NKG2D and DNAM-1 on tumor cells plays an important role in tumor opsonization by immune effector cell targeting. Various modulatory methods for up-regulating NKG2D and DNAM-1-ligands have been reported, and included chemotherapeutic agents and hyperthermia. Although there are many obstacles to the utilization of NKG2D and DNAM-1 for cancer therapy, combined treatments using immune cell therapy and chemotherapy that take advantage of NKG2D and DNAM-1 may be an ideal approach.",
author = "Takashi Morisaki and Hideya Ohnishi and Mitsuo Katano",
year = "2012",
month = "6",
language = "English",
volume = "32",
pages = "2241--2247",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6",

}

TY - JOUR

T1 - Cancer immunotherapy using NKG2D and DNAM-1 systems

AU - Morisaki, Takashi

AU - Ohnishi, Hideya

AU - Katano, Mitsuo

PY - 2012/6

Y1 - 2012/6

N2 - Although tumor antigen-specific immunotherapy, such as dendritic cell vaccine, has recently emerged as a promising clinical approach, one limitation of tumor antigen- and T-cell receptor (TcR)- specific immunotherapy is antigen-specific inhibition by antigen-specific regulatory T-cell and myeloid suppressor cells. Therefore, immunotherapy using a TcR-independent mechanism may be an alternative immunotherapeutic strategy. NKG2D (natural killer, group 2, member D) and DNAX accessory molecule-1 (DNAM-1) are both activated receptors that are strongly expressed on T-cells, γδT-cells, and NK cells. Therefore, the expression of ligands for NKG2D and DNAM-1 on tumor cells plays an important role in tumor opsonization by immune effector cell targeting. Various modulatory methods for up-regulating NKG2D and DNAM-1-ligands have been reported, and included chemotherapeutic agents and hyperthermia. Although there are many obstacles to the utilization of NKG2D and DNAM-1 for cancer therapy, combined treatments using immune cell therapy and chemotherapy that take advantage of NKG2D and DNAM-1 may be an ideal approach.

AB - Although tumor antigen-specific immunotherapy, such as dendritic cell vaccine, has recently emerged as a promising clinical approach, one limitation of tumor antigen- and T-cell receptor (TcR)- specific immunotherapy is antigen-specific inhibition by antigen-specific regulatory T-cell and myeloid suppressor cells. Therefore, immunotherapy using a TcR-independent mechanism may be an alternative immunotherapeutic strategy. NKG2D (natural killer, group 2, member D) and DNAX accessory molecule-1 (DNAM-1) are both activated receptors that are strongly expressed on T-cells, γδT-cells, and NK cells. Therefore, the expression of ligands for NKG2D and DNAM-1 on tumor cells plays an important role in tumor opsonization by immune effector cell targeting. Various modulatory methods for up-regulating NKG2D and DNAM-1-ligands have been reported, and included chemotherapeutic agents and hyperthermia. Although there are many obstacles to the utilization of NKG2D and DNAM-1 for cancer therapy, combined treatments using immune cell therapy and chemotherapy that take advantage of NKG2D and DNAM-1 may be an ideal approach.

UR - http://www.scopus.com/inward/record.url?scp=84864530880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864530880&partnerID=8YFLogxK

M3 - Review article

C2 - 22641658

AN - SCOPUS:84864530880

VL - 32

SP - 2241

EP - 2247

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6

ER -